OLANZAPINE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

OLANZAPINE

Saadav alates:

JUBILANT GENERICS LIMITED

ATC kood:

N05AH03

INN (Rahvusvaheline Nimetus):

OLANZAPINE

Annus:

7.5MG

Ravimvorm:

TABLET

Koostis:

OLANZAPINE 7.5MG

Manustamisviis:

ORAL

Ühikuid pakis:

30/100/1000

Retsepti tüüp:

Prescription

Terapeutiline ala:

ATYPICAL ANTIPSYCHOTICS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0128783004; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2014-01-16

Toote omadused

_Pr_
_Olanzapine _
_Page 1 of 55 _
PRODUCT MONOGRAPH
PR
OLANZAPINE
Olanzapine Tablets
2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg
Manufacturer Standard
Antipsychotic Agent
MANUFACTURER:
Jubilant Generics Limited
1-A, Sector -16A, Institutional Area,
Noida -201301, Uttar Pradesh, India
DATE OF REVISION: April 7, 2020
IMPORTER AND DISTRIBUTOR:
Pharmapar Inc.
1565 boul. Lionel-Boulet,
Varennes QC J3X 1P7
SUBMISSION CONTROL NO: 237756
_Pr_
_Olanzapine _
_Page 2 of 55 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL
USE............................................................................3
CONTRAINDICATIONS
................................................................................................4
WARNINGS AND
PRECAUTIONS...............................................................................4
ADVERSE
REACTIONS...............................................................................................13
DRUG INTERACTIONS
...............................................................................................26
DOSAGE AND
ADMINISTRATION............................................................................28
OVERDOSAGE
.............................................................................................................29
ACTION AND CLINICAL PHARMACOLOGY
.........................................................30
STORAGE AND
STABILITY.......................................................................................32
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................32
PART II: SCIENTIFIC INFORMATION
........................................................................33
PHARMACEUTICAL
INFORMATION.....................................................................33
CLINICAL
TRIALS..........................................................................